Advertisement
UK markets closed

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • FTSE 250

    19,391.30
    -59.37 (-0.31%)
     

  • AIM

    744.89
    -0.40 (-0.05%)
     

  • GBP/EUR

    1.1635
    -0.0049 (-0.42%)
     

  • GBP/USD

    1.2400
    -0.0038 (-0.31%)
     

  • Bitcoin GBP

    52,013.51
    +793.38 (+1.55%)
     

  • CMC Crypto 200

    1,387.36
    +74.74 (+6.04%)
     

  • S&P 500

    4,986.21
    -24.91 (-0.50%)
     

  • DOW

    37,920.05
    +144.67 (+0.38%)
     

  • CRUDE OIL

    82.94
    +0.21 (+0.25%)
     

  • GOLD FUTURES

    2,407.50
    +9.50 (+0.40%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • HANG SENG

    16,224.14
    -161.73 (-0.99%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • CAC 40

    8,022.41
    -0.85 (-0.01%)
     
Property:

11 beautiful homes with glorious garden rooms

Investing in a home with a garden room will enable you to enjoy your outside space whatever the weather

Should You Get Rid of Aerie Pharmaceuticals (AERI) Now?

Zacks

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Aerie Pharmaceuticals, Inc. AERI, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in AERI.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen five estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $4.14 a share a month ago to its current level of loss of $4.72.

Also, for the current quarter, Aerie Pharmaceuticals has seen three downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of $1.02 a share from a loss of 73 cents over the past 30 days.

The stock also has seen some pretty dismal trading lately, as the share price has dropped 25.1% in the past month.

Aerie Pharmaceuticals, Inc. Price and Consensus

Aerie Pharmaceuticals, Inc. Price and Consensus | Aerie Pharmaceuticals, Inc. Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical - Drugs industry, you may instead consider a better-ranked stock - BioSpecifics Technologies Corp. BSTC. The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank stocks here.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
BioSpecifics Technologies Corp (BSTC) : Free Stock Analysis Report
 
Aerie Pharmaceuticals, Inc. (AERI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research